



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

613.ACUTE MYELOID LEUKEMIAS: CLINICAL AND EPIDEMIOLOGICAL

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

David Martinez-Cuadron, PhD¹, Blanca Boluda², Jesús Lorenzo Algarra³, Juan Miguel Bergua Burgues⁴, Rebeca Rodriguez Veiga, MD⁵, Pilar Martinez Sanchez, MD⁶, Josefina Serrano, MD⁷, Fernando Jesús Ramos-Ortega, MD⁸, Jose A. Pérez-Simón⁹, Mar Tormo, MD¹⁰, Jose Luis Lopez Lorenzo, MD¹¹, Esperanza Lavilla¹², Teresa Bernal Del Castillo, MD PhD¹³, Carlos Rodríguez-Medina, MD PhD¹⁴, Maria Carmen GARCIA Garay¹⁵, Maria Jose Sayas Lloris¹⁶, Cristina Gil, MD¹⁷, Maria Teresa Olave Rubio¹⁸, Raimundo Garcia Boyero¹⁹, Susana Vives²⁰, Maria Angeles Foncillas²¹, Jorge Labrador²², Francisco Ibañez²³, Ana Cabello²⁴, Pilar Herrera Puente²⁵, Bernardo Javier González González, MD²⁶, Eva Barragán, PhD²⁷, Claudia Sargas²⁸, Rosa Ayala, MD⁶, Carmen Chillon²⁹, Pau Montesinos, PhDMD³⁰

¹Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

²Hospital Universitari I Politècnic La Fe, Valencia, ESP

³Hospital General de Albacete, Albacete, ESP

⁴Hospital San Pedro de Alcántara, Cáceres, Spain

⁵Hospital Universitario i Politecnico La Fe, VALENCIA, ESP

⁶Hospital Universitario 12 de Octubre, Madrid, Spain

⁷Hospital Universitario Reina Sofía, IMIBIC, Córdoba, ESP

⁸Hospital Universitario de León, León, Spain

⁹Instituto de Biomedicina de Sevilla (IBIS), Servicio de Hematología, Hospital Universitario Virgen del Rocío and Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Sevilla, Spain

¹⁰Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain

¹¹Fundacion Jimenez Diaz, Madrid, ESP

¹²Hospital Universitario Lucus Augusti, Lugo, Spain

¹³Hospital Universitario Central de Asturias, Oviedo, Spain

¹⁴Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, ESP

¹⁵Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

¹⁶Hospital Dr. Peset, ZARAGOZA, ESP

¹⁷Hospital General Universitario de Alicante, Alicante, ESP

¹⁸Hospital Clínico Universitario Lorenzo Blesa, Zaragoza, ESP

¹⁹Hospital General Universitario de Castellon, Castellon, Spain

²⁰Hospital Germans Trias i Pujol, Badalona, ESP

²¹Hospital Universitario Infanta Leonor, Madrid, ESP

²²Hospital Universitario de Burgos, Universidad Isabel I, Burgos, ESP

²³Hospital General Universitario de Valencia, Valencia, Spain

²⁴Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, ESP

²⁵Hospital Universitario Ramon y Cajal, Madrid, ESP

²⁶Hospital Universitario de Canarias, Tenerife, Spain

²⁷Molecular Biology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain

²⁸Hospital La Fe, Valencia, ESP

²⁹Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

³⁰Hospital Universitari i Politecnico la Fe, Valencia, Spain

Background: Current treatment of unfit acute myeloid leukemia (AML) patients include hypomethylating agents (HMA) with or without venetoclax, low-dose cytarabine (LDAC), and supportive care only. Recently, the combination of azacytidine with ivosidenib, an IDH1 inhibitor, has showed a significant improvement in survival in unfit patients with IDH1 mutated (IDH1mut) AML compared to azacytidine plus placebo. Real world studies analyzing outcomes of IDH1mut AML patients are scarce.

Aims: This study aims to assess retrospectively the characteristics, therapeutic approaches, and outcomes of unfit patients with AML in an unselected population reported to the multicentric PETHEMA registry according to IDH mutational status. We present here a first interim analysis, as the study is aimed to enroll 3500 patients.

Methods: AML unfit patients reported to PETHEMA registry between January 2015 and June 2022 were included in the study, regardless of their therapeutic approach. IDH1 mutational status was analyzed with next generation sequencing (NGS) and polymerase chain reaction (PCR) techniques performed in central labs from PETHEMA group, as well as locally as per standard practice. All clinical records were reviewed from diagnosis to death/last follow-up and data were analyzed with R statistical software.

Results: From 9398 patients reported to the PETHEMA registry between 2015 and 2022, 4533 patients had information on IDH1 mutational status. Of them, 2096 patients were unfit for intensive chemotherapy, and therapeutic approach was available in 1255 patients who were evaluable for this interim report. Median age was 75 years, 716 (57%) were male, 312 (35%) had adverse cytogenetic-risk. Overall, 141 (11%) had IDH1mut [106 (12.4%) by NGS and 77 (9.9%) by PCR only] and 1114 (89%) had no IDH1 mutation (IDH1wt). There were differences between IDH1mut vs IDH1wt cohorts regarding white blood cells (WBC) count ($P=0.003$), platelets count ($P=0.002$), bone marrow blasts percentage ($P<0.001$), MRC cytogenetic risk ($P=0.02$) and NPM1 mutational status ($P<0.001$). More detailed information is shown in Table 1.

Regarding treatments, 176 (15%) patients received only best supportive care (BSC), 293 (23%) were included in non-intensive clinical trials, 433 (34%) received HMAs, 281 (22%) LDAC schedules and 62 (5%) venetoclax plus HMA or LDAC (VEN). From 818 patients with available response, 261 (32%) achieved complete remission (CR) or CR with incomplete recovery (CRi), 105 (13%) partial remission, 305 (37%) were resistant and 147 (18%) died before being assessed. No statistical differences were observed between IDH1mut and IDH1wt groups ($P=0.18$).

Median overall survival (OS) was 5.9 months (CI95, 5.3-6.7), with no differences in IDH1mut and IDH1wt cohorts [median 7.7 months (CI95, 5.9-11.2) vs 5.6 (CI95, 5-6.4)], with a 2y-OS of 15% (9.7-24.5) vs 15% (12.9-18.2), respectively ($P=0.24$). Median OS was 7.9 (CI95, 6.8-9.3) in patients receiving active treatment. Patients receiving VEN schedules had a median OS of 11.1 months (CI95, 9.4-14.1) vs 10.5 (CI95, 8.2-13.0) in patients included in clinical trials vs 8.3 (CI95, 6.7-10.0) in those receiving HMA vs 5.5 (CI95, 4.5-6.8) treated with LDAC-based schemes vs 0.4 (CI95, 0.3-0.7) in BSC patients ($P<0.001$). Figure 1 shows OS according to therapeutic approach in all patients.

According to the therapeutic approach, IDH1mut patients included in clinical trials had a median OS of 16.8 (CI95, 6.0-NA) vs 10.6 months (CI95, 9.9-NA) in patients receiving VEN schedules vs 9.0 (CI95, 6.5-14.5) in those receiving HMA vs 7.0 (CI95, 5.5-12.7) with LDAC-based vs 0.6 (CI95, 0.2-3.7) in BSC patients ($P<0.001$).

Conclusion: We show a prevalence of 11% of IDH1 mutation among patients considered unfit to receive intensive chemotherapy. Although there were differences between IDH1mut and IDH1wt subgroups in some variables with demonstrated prognostic impact, no significant differences were observed in response to treatment or OS.

This study was partially supported by Servier.

Disclosures Martinez-Cuadron: Pfizer: Other: Travel, Accommodations; Otsuka: Consultancy, Other: Travel, Accommodations; Astellas: Consultancy, Speakers Bureau. **Bergua Burgos:** Fundesalud. Grants of Europea funds. **Daychii:** Research Funding; Daychii: Consultancy; Hospital San Pedro de Alcántara. Servicio de Hematología. Cáceres. SPAIN: Current Employment. **Tormo:** BMS: Honoraria; Astellas: Honoraria; Pfizer: Honoraria; MSD: Honoraria; AbbVie: Honoraria. **Lavilla:** Sanofi, Janssen, Incyte, SOBI; Belgene: Consultancy, Honoraria. **Bernal Del Castillo:** Otsuka: Consultancy; Jazz: Consultancy; AbbVie: Consultancy. **Ayala:** BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Speakers Bureau. **Montesinos:** Ryvu: Consultancy; Astellas: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; GILEAD: Consultancy; OTSUKA: Consultancy; BEIGENE: Consultancy; INCYTE: Consultancy; NERVIANO: Consultancy; Celgene: Consultancy; Janssen: Speakers Bureau; Kura oncology: Consultancy; Menarini-Stemline: Consultancy, Research Funding; Jazz pharma: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy, Other, Research Funding; Daiichi Sankyo: Consultancy, Research Funding.

Table 1. Characteristics IDH1mut vs IDH1wt

Characteristic	Overall		IDH1 mutated		IDH1 wild type		P value
	Median (IQR)	n (%)	Median (IQR)	n (%)	Median (IQR)	n (%)	
Total		1255 (100)	141 (100)		1114 (100)		
Age, years	75 (71-80)	1255 (100)	75 (71-80)	141 (100)	75 (70-80)	1114 (100)	0.82*
<60		43 (3)		7 (5)		36 (3)	
60-69		207 (16)		20 (14)		187 (17)	
70-79		698 (55)		78 (55)		610 (55)	
80-89		303 (24)		34 (24)		269 (24)	
≥90		14 (1)		2 (1)		12 (1)	
WBC, ×10⁹/L	6.9 (2.3-27.4)	1149 (100)	4.4 (1.8-17.4)	130 (100)	7.2 (2.3-29.2)	1019 (100)	0.003*
<5		501 (44)		70 (54)		431 (42)	0.02
5-10		150 (13)		14 (11)		136 (13)	
10-50		312 (27)		35 (27)		277 (27)	
≥50		186 (16)		11 (8)		175 (17)	
MRC Cytogenetic risk		693 (100)		96 (100)		797 (100)	
Favorable		24 (3)		1 (1)		23 (3)	0.02
Intermediate		557 (62)		72 (75)		485 (61)	
Adverse		312 (35)		23 (24)		289 (36)	
NPM1		966 (100)		115 (100)		851 (100)	
Positive		193 (20)		38 (33)		155 (18)	<0.001
Negative		773 (80)		77 (67)		696 (82)	
Therapeutic approach		1255 (100)		141 (100)		1114 (100)	
HMA		433 (34)		53 (38)		380 (34)	0.89
VEN-based		62 (5)		8 (6)		54 (5)	
LDAC-based		281 (22)		31 (22)		250 (22)	
Clinical Trial		293 (23)		30 (21)		263 (24)	
Supportive care		186 (15)		19 (13)		167 (15)	

IQR: interquartile range; WBC: White Blood Cells; BM: Bone Marrow; MRC: Medical Research Council; IDH1: isocitrate dehydrogenase 1; LDAC, low-dose cytarabine; NPM1: Nucleophosmin1; HMA: hypomethylating agents; VEN: venetoclax; * P compare continuous variables

Figure 1. OS according to therapeutic approach in all patients




Figure 1

<https://doi.org/10.1182/blood-2023-189800>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/4223/2190282/blood-824-main.pdf by guest on 18 May 2024